Ignite Creation Date:
2024-05-05 @ 6:37 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00510510
Status:
COMPLETED
Last Update Posted:
2012-05-21
First Post:
2007-08-01
Brief Title:
Safety and Tolerability of 28 Days Treatment With Glycopyrronium Bromide NVA237 100 or 200 µg Once a Day in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
A Randomized Double-blind Placebo Controlled Parallel Group Multi-center Study to Assess the Safety and Tolerability of 28 Days Treatment With NVA237 100 or 200 µg Once a Day in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease COPD
Status:
COMPLETED
Status Verified Date:
2012-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study assessed the safetytolerability of 28 days of treatment with NVA237 100 µg and 200 µg once a day compared to placebo in patients with moderate or severe Chronic Obstructive Pulmonary Disease COPD
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None